EC Healthcare, which describes itself as Hong Kong's largest non-hospital medical group, and New Horizon Health, a Chinese cancer screening company, have formed an exclusive partnership to launch and distribute CerviClear in Hong Kong. New Horizon describes CerviClear as the first urine-based test for HPV detection and cervical cancer screening, covering all 14 high-risk types of the virus from a sample collected at home. The companies say the product holds a CE mark and is cleared for sale in Hong Kong and the Greater Bay Area.
EC Healthcare's executive director and co-chief executive, Leslie Lu, described the partnership as part of a strategy of working with upstream biotechnology partners, and New Horizon's chief executive, Zhu Yeqing, said the product avoids a hospital visit and the discomfort of a clinical sample.
Convenience is not the same as coverage
Cervical cancer is unusual among cancers in that it has a known cause and can be prevented through screening and vaccination. The barrier in much of Asia is not the science but the sample: a pelvic examination is part of why many women who should be screened are not. A test that needs only urine, collected privately, addresses exactly that barrier, which is why the product is worth attention.
What it does not address is what happens after a result. A positive HPV test still leads to a clinical examination, and a home test bought privately reaches the women who can afford it, not the ones least likely to have been screened. The CE mark certifies the test; it does not make screening routine.
New Horizon points to its three approved products in China as evidence that it can commercialise. Whether a private home-sampling test lowers the cost of finding cervical cancer early, or simply shifts detection further towards those already paying for their care, is the question the partnership leaves open.
